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Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection
in young children globally, but little is known about within-host RSV diversity. Here, we
characterised within-host RSV populations using deep-sequencing data from 319 nasophar-
yngeal swabs collected during 2017–2020. RSV-B had lower consensus diversity than RSV-A
at the population level, while exhibiting greater within-host diversity. Two RSV-B consensus
sequences had an amino acid alteration (K68N) in the fusion (F) protein, which has been
associated with reduced susceptibility to nirsevimab (MEDI8897), a novel RSV monoclonal
antibody under development. In addition, several minor variants were identified in the anti-
genic sites of the F protein, one of which may confer resistance to palivizumab, the only
licensed RSV monoclonal antibody. The differences in within-host virus populations
emphasise the importance of monitoring for vaccine efficacy and may help to explain the
different prevalences of monoclonal antibody-escape mutants between the two subgroups.
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Human respiratory syncytial virus (RSV) is the leadingcause of lower respiratory tract infection (LRTI) in youngchildren, globally responsible for around 33 million epi-
sodes of LRTI in children under 5 years of age annually with a
disproportionately high burden in infants younger than 1 year of
age1. Repeated infection is common throughout life2, usually
resulting in mild symptoms, but it can also cause serious disease
in older (age ≥65 years) or immunocompromised adults and
people with chronic cardiopulmonary disease3. Despite decades
of effort, there is no efficacious antiviral for treatment or licensed
vaccine to prevent RSV infection, and thus the standard of care is
supportive management only. Palivizumab, an RSV-specific
humanised monoclonal antibody, is the only available immuno-
prophylactic agent. It requires multiple administrations over the
RSV season and is very expensive, so its use is limited to the
highest-risk populations, namely infants born preterm and those
with congenital heart disease, chronic pulmonary disorders or
severe combined immunodeficiency4.
RSV is a negative-sense single-stranded RNA virus with a
genome containing ten genes. The F gene encodes the fusion (F)
glycoprotein, which mediates the fusion of host cell and viral
membranes. The F protein is the main target for antibody-
mediated neutralisation, and has been the focus of the develop-
ment of vaccines and monoclonal antibodies5. Through the
fusion process, the F protein changes from the prefusion to
postfusion conformation. Several antigenic sites (neutralising
epitopes in particular) have been located on the surface of the F
protein. Antibodies exclusively targeting prefusion-specific anti-
genic sites (e.g. sites + and V) are more potent than those
targeting sites that can be found in both conformations (e.g. sites
I, II, IV)6. Nirsevimab (MEDI8897), a recombinant human
monoclonal antibody currently in phase 3 clinical trials, exclu-
sively targets antigenic site +7, and suptavumab (REGN2222),
another prefusion-specific monoclonal antibody, binds antigenic
site V8. Palivizumab and its affinity-enhanced variant,
motavizumab9, target antigenic site II, and antibody 101F binds
antigenic site IV10. Mutations in the antigenic sites that confer
resistance to monoclonal antibodies have been identified. For
example, mutants with N262S/Y, N268I, K272E/N/M/T/Q or
S275F/L in the F protein are less susceptible to palivizumab11–13,
and nirsevimab has reduced neutralising activity against mutants
with N67I/N208Y, N208S/D, K68N/N201S or K68N/N208S in
the F protein7.
The G gene encodes the attachment (G) glycoprotein, a
transmembrane protein responsible for viral attachment. The
extracellular portion (ectodomain) of the G protein consists of
two hypervariable mucin-like regions flanking a conserved central
domain (CCD)14. The CCD, containing antigenic sites γ1 and γ2,
has been shown to be a target for neutralising antibodies15 and is
another focus of vaccine development16,17. Outside the CCD, the
mucin-like regions also have multiple antigenic sites though less
well-defined18. The mucin-like region II (second hypervariable
region) has been shown to have hypermutation at the population
level and has thus been used widely in phylogenetic analyses19.
The two subgroups of RSV (A and B) co-circulate in epidemics,
and both exhibit rapid evolutionary dynamics20. Molecular epi-
demiology and evolutionary dynamics of RSV have been exten-
sively studied at the consensus level; however, little is known
about virus populations in each infected individual (i.e. within-
host or intrahost virus diversity). Using high-throughput whole-
genome sequencing, it is now possible to sequence viruses in
sufficient depth to obtain a complete picture of within-host
populations. A previous study showed that within-host RSV
diversity increased in an immunocompromised infant with per-
sistent RSV infection following a haematopoietic stem cell
transplant, and palivizumab escape mutants emerged after
multiple administrations of this drug21. Another study demon-
strated that RSV-A exhibited greater within-host virus diversity in
experimentally infected adults than in naturally infected infants22.
However, these results were limited to RSV-A infection and did
not look at natural infections in adult populations. Analysing
within-host virus genetic diversity in infections that represent
general seasonal epidemics can aid understanding of the patterns
of virus evolution and its driving forces, informing the develop-
ment of preventative and treatment measures.
In this study, we seek to characterise within-host RSV popu-
lations for the two subgroups, RSV-A and RSV-B, using deep
sequencing of samples collected from participants in three pro-
spective clinical studies. We find that RSV-B exhibits greater
within-host diversity than RSV-A, with two RSV-B consensus
strains and one RSV-B minor variant likely conferring resistance
to nirsevimab or palivizumab. We also show that temporal
changes of intrahost viral populations follow stochastic patterns.
Our work highlights the importance of continued genetic sur-
veillance of RSV to ensure the effectiveness of future RSV vac-
cines and therapeutics.
Results
Sample population. We sequenced RSV from 858 nasophar-
yngeal swabs collected from 459 RSV-infected patients in the
United Kingdom, Spain and the Netherlands during 2017–2020.
Of these, 327 samples had sufficient viral load to generate more
than 10,000 unique (deduplicated) RSV reads. After removing
five samples containing both RSV-A and RSV-B, 322 samples
were included in the within-host virus diversity analysis.
Sequencing was carried out in four batches, with 11, 113, 41 and
157 of the included samples from each batch respectively (Sup-
plementary Table 1). The 322 samples were collected from 267
different participants, among which 34 participants had multiple
samples (mean 2.6, range 2–5) collected on different days (ran-
ging from 1 to 8 days apart).
Cumulative minor allele frequencies and minor variants.
Genomic positions with a read depth of less than 200 were
excluded from the analysis. Nearly 90% of the samples had ≥80%
of the genome passing this threshold. Three samples had a sig-
nificantly high mean cumulative minor allele frequency (MAF)
per sample: 0.52% (from an RSV-A-infected infant; batch 4),
0.19% (from an RSV-B-infected adult; batch 2) and 0.17% (from
an RSV-B-infected infant; batch 4). These samples presumably
represented a real or artefactual mixture of genetically distinct
strains of the same RSV subgroup and were thus excluded from
the following analysis. The sources and sequencing yields of the
remaining 319 samples (collected from 264 participants) are
shown in Table 1.
The median of the mean cumulative MAF per sample was
0.039% (range 0.025–0.068%) for the 319 samples. The distribu-
tions of the mean cumulative MAF per sample were significantly
different between samples from different sequencing batches
(Supplementary Fig. 1a), likely due to the differences in the ratio
of duplicate read counts to total RSV read counts (percent
duplication rate) between batches (Supplementary Table 1). After
adjusting for the observed batch effects (e.g. Supplementary
Fig. 1b), RSV-B samples had a higher mean cumulative MAF per
sample than RSV-A samples (median of the original data: 0.042%
vs. 0.037%; multiple linear regression with batch and the number
of unique RSV reads as covariates, P= 0.016; Mann–Whitney U-
test on standardised data, P= 0.016).
On average, each sample had 3.7 minor variants (range 0–30;
defined as variants with a frequency of ≥3%). Of the samples,
18.8% (60/319) did not have any minor variants. An inverse
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correlation was noted between the number of unique RSV reads
and the number of minor variants (r=−0.41, P= 4.2 × 10−14;
Supplementary Fig. 2), consistent with a greater variance of MAF
when the sampling fraction was small (i.e. few unique reads were
sequenced)23. Variation rarely occurred at the same genomic
position in different samples. Among all minor variants found in
this study, only 5.9% (57/972) were shared by multiple samples
(excluding 17 minor variants only shared by sequential samples
from the same participants), usually no more than five samples.
However, there was one minor variant shared by 59% (85/144) of
the RSV-B samples, with a frequency between 3 and 11%. This
minor variant had a G to A substitution at position 3403 of the L
gene, causing an amino acid alteration from glutamic acid to
lysine at position 1135 (E1135K) of the RNA-dependent RNA
polymerase.
Potential antigenic variants. The sequences encoding the anti-
genic sites of the F protein were highly conserved at the consensus
level in this study. However, two RSV-B isolates from two infant
participants, both of whom had only one sample collected, had an
A to T substitution at nucleotide position 204 of the F gene. This
substitution results in an amino acid alteration from lysine to
asparagine (K68N), which in a previous study was associated with
a fourfold reduction in susceptibility to nirsevimab neutralisation
in vitro7. No minor variant was found at this position in these
two samples.
The frequencies and distribution of all minor variants across
the coding sequence of the F gene are shown in Fig. 1a. There
were one, eight, two and three minor variants identified in the
antigenic sites +, II, IV and V of the F protein, respectively
(Table 2). 0, 6.0% (6/100) and 1.6% (2/124) of the participants
had potential antigenic variants (i.e. minor variants encoding a
nonsynonymous substitution in the antigenic sites) in the
2017–18, 2018–19 and 2019–20 RSV seasons, respectively. One
of these minor variants had two nucleotide substitutions with a
frequency of ≥3% in a single codon, encoding an amino acid
substitution from isoleucine to threonine at position 261 (I261T).
Other minor variants identified in the antigenic sites were from
different samples. To date, none of these variants have been
reported to confer resistance to monoclonal antibodies.
We also looked at the frequencies and distribution of minor
variants in the coding region of the G gene (Fig. 1b). The median
frequency of minor variants was significantly higher in the G gene
than in the F gene, either at potential antigenic sites (median:
9.3% vs. 4.6%; Mann–Whitney U-test, P= 0.022) or across the
whole coding sequences (median: 8.3% vs. 4.4%; Mann–Whitney
U-test, P= 0.004), consistent with previous studies identifying the
G gene as the most variable gene in the virus genome14. The
median minor variant frequency in the mucin-like region II of the
G gene (13.7%) was greater than that in the mucin-like region I
(9.2%), which was greater than that in the CCD (4.0%). However,
these differences were not statistically significant (Kruskal–Wallis
test, P= 0.20).
Pairwise nucleotide diversity. Within-host virus genetic diversity
was estimated as pairwise nucleotide diversity (see Methods).
Pairwise nucleotide diversity did not correlate with the number of
unique RSV reads after adjusting for the batch effects (Supple-
mentary Table 2 and Supplementary Fig. 3a), but was highly
consistent with the mean cumulative MAF per sample (r= 0.997,
P < 2.2 × 10−16; Supplementary Fig. 3b). The median pairwise
nucleotide diversity of the whole dataset was 0.0007 (range
0.0005–0.0014). Gene-wise comparisons showed that the L gene
had significantly higher pairwise nucleotide diversity than the
Table 1 Characteristics of RSV samples by subgroup.
RSV-A (N= 175) RSV-B (N= 144) P valuea
Host number 0.12b
Infants 141 115
Older adults 1 7
Host age, median (range)
Infants (month)c 4.5 (0.5–11.6) 4.3 (0.2–11.7) 0.72
Older adults (year) 69 75 (72–78) 0.19
Sample source 0.45
United Kingdom 74 64
Netherlands 58 53
Spain 43 27




Days between symptom onset and sample collection, median (range)d 4 (1–11) 4 (1–9) 0.11
Number of unique RSV read pairs ðlog 10Þ, median (range) 4.6 (4.0–5.8) 4.7 (4.0–5.9) 0.22
Batch 1 4.9 (4.1–5.5) 5.3 (4.4–5.6) 0.50
Batch 2 4.6 (4.0–5.6) 4.6 (4.0–5.9) 0.98
Batch 3 4.4 (4.0–4.8) 4.5 (4.0–5.5) 0.18
Batch 4 4.7 (4.0–5.8) 4.9 (4.0–5.6) 0.12
Minimum genome coverage (%) 99.9 100 0.37
Average depth of coverage, median (range) 3372 (696–7897) 3650 (525–7930) 0.41
Batch 1 2940 (696–6823) 4975 (1295–7601) 0.63
Batch 2 3561 (1092–7452) 3469 (1091–7930) 0.68
Batch 3 2045 (803–3224) 2258 (525–7157) 0.37
Batch 4 3736 (847–7897) 4505 (719–7798) 0.23
aUnless otherwise specified, chi-square tests with Yates’ continuity correction or Fisher’s exact tests were used for contingency analysis, and two-tailed Mann–Whitney U-tests were used to compare
numeric variables between subgroups.
bLogistic regression was used to adjust for sampling season. Samples were collected from older adults only in 2017–18 and 2018–19 RSV seasons, when RSV-B was the predominant circulating subgroup.
cOne infant with RSV-B infection had missing information on age.
dSix infants with RSV-A infection and five infants with RSV-B infection had missing information on the date of symptom onset.
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Fig. 1 Minor variants in the coding region of the F and G genes among 175 RSV-A and 144 RSV-B samples. a F gene. Shaded regions represent known
antigenic sites (neutralising epitopes in particular): red, prefusion-specific antigenic site + (target for nirsevimab); green, site II (target for palivizumab
and motavizumab); yellow, site IV (target for 101F) and blue, prefusion-specific site V (target for suptavumab). b G gene. The purple region represents the
conserved central domain (target for 3D3 and 2D10), flanked by highly variable mucin-like regions I (grey) and II (orange). Nirsevimab, palivizumab,
motavizumab, 101F, suptavumab, 3D3 and 2D10 are RSV-specific monoclonal antibodies. Each dot denotes a minor variant, coloured by subgroup. Black
dashed line represents minor allele frequency of 3%, used to define a minor variant. Positions are numbered from the first base of the coding sequence of
each gene according to the NCBI reference sequence (accession number NC_038235).
Table 2 Characteristics of minor variants within the antigenic sites of the fusion protein.
Nucleotide positiona Codon change Amino acid changeb Antigenic site Subgroup/country/season/
minor allele frequency (%)c
489 GAA:GAt E163D V A/GB/2018–19/3.4
A/GB/2018–19/6.1
495 AAC:AAt N165 V A/GB/2018–19/4.6
577 CCA:tCAd P193S + A/GB/2018–19/30.1
764 AGT:AaT S255N II A/ES/2019–20/13.2e
A/ES/2019–20/22.8e
B/GB/2018–19/3.6
782 ATC:Act I261T II A/ES/2018–19/4.6f
783 ATC:Act I261T II A/ES/2018–19/4.7f
810 CAG:CAa Q270 II B/NL/2017–18/3.2
B/NL/2017–18/6.2g
B/NL/2018–19/3.9
823 TCA:cCA S275P II B/GB/2018–19/3.1
1273 TCA:cCA S425P IV A/GB/2019–20/3.6
1311 AAC:AAt N437 IV A/NL/2019–20/8.0
aPositions are numbered from the first base of the coding sequence of the F gene according to the NCBI reference sequence (accession number NC_038235).
bPositions are numbered from the first methionine of the fusion protein according to the NCBI reference sequence (accession number NC_038235).
cGB denotes the United Kingdom; ES, Spain and NL, the Netherlands.
d55.7% (98/176) of the RSV-A samples had a consensus base of T, and all RSV-B samples had a consensus base of T at this position.
eThese two variants were found in samples collected from the same participant on day 2 (13.2%) and day 5 (22.8%) of hospitalisation, respectively. Samples collected from this participant on other days
(days 1, 3 and 4) did not have variants with a frequency of ≥3% at this position.
fThese two were co-occurring mutations, identified in the same minor variant.
gExcept for this variant, which was in a sample from an adult participant, other minor variants were identified in infant samples.
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NS2, P, SH and G genes, but the other genes did not have sig-
nificant differences in pairwise nucleotide diversity between each
other (Supplementary Fig. 4). These significant differences were
by definition due to the mean proportion of pairwise nucleotide
differences at each genomic position within the L gene instead of
the length of the L gene.
RSV-B had greater pairwise nucleotide diversity than RSV-A
after adjusting for the batch effects (multiple linear regression,
P= 0.044, Supplementary Table 2 and Fig. 2a), and older adults had
a more diverse intrahost RSV-B population than infants (multiple
linear regression, P= 0.0006, Supplementary Table 2 and Fig. 2b).
The subgroup difference was still significant if excluding adult
samples (Mann–Whitney U-tests on standardised data, P= 0.039).
The number of RSV reads and the duration between symptom
onset and sample collection were similar between both RSV
subgroups and between both age groups. Samples collected from
different countries or seasons or patients with different severity of
RSV infections did not have significant differences in pairwise
nucleotide diversity (Supplementary Table 2).
Genetic distance. Within-host diversity levels between samples
were compared using pairwise Manhattan distances24 at consensus-
identical positions, where allele frequencies below the 3% threshold
were converted to 0. In contrast, consensus variations between
samples were compared using pairwise patristic distances, which are
phylogenetic distances on RSV phylogenies (Supplementary Fig. 5).
To eliminate the batch effects, we only included pairwise distances
between samples in the second batch (n= 112; excluding one
outlier). To reduce potential bias from geographical and temporal
differences, only pairwise distances between samples from the same
country and the same season were calculated.
Serial sample pairs (i.e. pairs with both samples collected from
the same participant) had within-host diversity levels comparable
to those of samples from different participants (range: 0–3.34 vs.
0–5.03), despite having identical or nearly identical consensus
sequences, as indicated by their small patristic distances (range
2.0 × 10−6− 7.5 × 10−5). Excluding the serial sample pairs, RSV-
B sample pairs had significantly greater within-host diversity
levels than RSV-A pairs (median: 1.24 vs. 0.86), whereas the
comparison of consensus sequences showed the opposite effect
(Fig. 2c, d). Pairwise patristic distances between RSV-A samples
formed three clusters, corresponding to the three main clades of
the phylogenetic tree (Supplementary Fig. 5a). When using all
allele frequencies, including those below 3% MAF, to calculate
Manhattan distances, RSV-B sample pairs still had significantly
greater pairwise Manhattan distances than RSV-A pairs (median:
20.5 vs. 18.2, P= 8.2 × 10−58; Supplementary Fig. 6).
Temporal change of intrahost virus population. Putting all
samples together, standardised pairwise nucleotide diversity did
not have a significant temporal change within 7 days of symptom
onset (R2= 0.008; P= 0.122). For the 34 participants with mul-
tiple samples collected daily during hospitalisation, pairwise
nucleotide diversity was also evaluated in each set of serially
collected samples, excluding those sequenced in different batches
(Fig. 3). No significant trend was noted either in each participant
or when combining all samples and adjusting for the batch
effects. The only exception was the samples from GB-058, where
pairwise nucleotide diversity increased by 0.000063 daily (95%
confidence interval, 0.000046 to 0.000080; P= 0.004). This
patient was a 19-day-old preterm neonate (gestational age of
33 weeks 6 days) with severe RSV infection requiring intensive
care and mechanical ventilation.
The changes in minor variants and variant frequencies in the
serial samples were also evaluated at polymorphic sites where
minor alleles were identified at more than three time points
(Fig. 4). Of these minor variants, 79% had a nonsynonymous
substitution. Only one minor variant with a G to A substitution at
position 3403 of the L gene from participant NL-091, which was
shared by 71 participants (85 samples), remained above the 3%
threshold throughout the sampling period. This patient was a 42-
day-old previously healthy infant with severe RSV infection
requiring intensive care and mechanical ventilation. All other
variants (including the aforementioned variant in other partici-
pants) were only detected either early, late or intermittently
during the course of sample collection.
Discussion
In this study, we sequenced 858 nasopharyngeal samples collected
in three clinical studies during 2017–2020 and profiled within-
















































































RSV−A RSV−B Older adults Infants RSV−A RSV−B RSV−A RSV−B
a b c d
Fig. 2 Z-score standardised pairwise nucleotide diversity and pairwise genetic distances. a Comparison of standardised pairwise nucleotide diversity
between 175 RSV-A and 144 RSV-B samples. b Comparison of standardised pairwise nucleotide diversity of RSV-B between seven adult samples and 137
infant samples. RSV-A isolates were excluded from this comparison because only one adult had RSV-A infection. c Comparison of pairwise Manhattan
distances. d Comparison of pairwise patristic distances. Only pairwise distances between samples from the second sequencing batch, the same country,
the same season and different participants were included in c and d (650 RSV-A pairs and 656 RSV-B pairs). Each dot represents an individual sample in a
and b, and a sample pair in c and d. Two-tailed Mann–Whitney U-tests were used to evaluate the significance of the differences. P values are shown above
the plots. For a and b, the centre line of each box denotes the median; box limits, the first and third quartiles; whiskers, the highest and lowest values within
1.5 times the interquartile range from the box limits and outlying points, outliers. For c and d, the violin plots summarise the distribution of the data, and the
black dots denote the median value of each group.
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RSV-B had greater within-host diversity than RSV-A, whereas
RSV-A had greater consensus diversity than RSV-B. Two RSV-B
isolates’ consensus sequences had a mutation in the F protein
(K68N), previously associated with reduced susceptibility to nir-
sevimab neutralisation. Several other minor variants were also
identified in the antigenic sites of the F protein. None of these
variants have been reported before except for S255N25, whose
susceptibility to monoclonal antibodies has not been examined.
Stochastic (random) patterns were found in the temporal changes
of within-host virus diversity and minor variants.
Low input genetic material (i.e. viral load) has been shown to
reduce the sensitivity and specificity of variant calling26. In this
study, we applied the quantitative methodology of targeted
metagenomics to library construction and used the number of
unique RSV reads as a proxy for viral load27. The inclusion cri-
terion of more than 10,000 unique RSV reads corresponded with
GB−099 GB−108 GB−137 GB−140 GB−146 NL−091
ES−054 ES−067 ES−074 GB−058 GB−066 GB−082





















Fig. 3 Temporal change of pairwise nucleotide diversity. Pairwise nucleotide diversity of serial samples collected at more than two time points and
sequenced in the same batch are shown here. Three participants whose samples were sequenced in different batches and 19 participants who had only two




















































































ES−054/NS1/121/T ES−054/L/5692/A* NL−091/F/810/G NL−091/L/3403/G*
ES−067/L/1532/G* GB−058/L/3403/G* GB−140/L/508/T* GB−140/L/3403/G* GB−140/L/4409/C*
ES−067/M/692/A* NL−091/G/296/T* NL−091/G/566/T* ES−067/F/764/G* ES−067/F/1062/A
GB−108/L/2327/G* GB−108/L/3454/G* NL−091/L/182/T* NL−091/L/1930/G* NL−091/L/3482/A*
ES−067/L/892/A* ES−054/NS2/183/T ES−054/F/415/G* GB−108/M/204/C GB−108/L/1957/C*
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5






















































































































Fig. 4 Temporal change in minor alleles. Minor alleles and allele frequencies are shown at polymorphic sites within the coding sequence of the serial
samples, where minor alleles were detected at ≥3 time points. The grey dashed lines represent the 3% threshold, which defines a minor variant. Panels are
labelled with the participant ID, followed by the gene name, the nucleotide position and the consensus base. Asterisks denote nonsynonymous
substitutions. Letters in the plots denote minor allele bases. Panels are ordered by the trend of the change: increased, decreased and fluctuated. Positions
are numbered from the first base of the coding sequence of each gene according to the NCBI reference sequences with the accession numbers of
NC_038235 and NC_001781 for RSV-A and RSV-B, respectively.
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a viral load of ~2.4 × 106 copies/mL and above, sufficient input
levels for accurate minority variant calling28. Given a large
number of samples in this study, batching was required for
sequencing, resulting in variable percent duplication rates and
hence some batch effects on diversity metrics. We adopted two
approaches to account for the batch effects on the comparisons of
mean cumulative MAF per sample and pairwise nucleotide
diversity: (i) including batch as a regression covariate and (ii)
standardising the values within each batch to z-scores (see
Methods for details). Both methods showed the same significant
findings, making cross-batch comparisons robust. To avoid any
residual bias, for pairwise comparisons of genetic distances we
used only samples from the same batch (batch 2), which had very
high percent duplication rates and similar read counts for RSV-A
and RSV-B (Table 1 and Supplementary Table 1), consistent with
capture saturation, and from which we could be confident of
recovering the full range of intrahost diversity.
The extent of intrahost virus diversity depends not only on the
rate of virus evolution (partly associated with the ability of
proofreading for viral replication errors) but also on the duration
of infection. RNA viruses generally have a higher mutation rate
than DNA viruses29, and are usually not able to correct the errors
of viral replication, which DNA viruses can30. In our study, RSV
had greater pairwise nucleotide diversity than has been reported
for influenza virus, another RNA virus causing acute respiratory
infection (range 0.0005–0.0014 vs. 0–0.000231). RSV intrahost
diversity appears to be comparable with, or slightly higher than,
that of the DNA viruses in the family Herpesviridae, which cause
chronic infections32, but up to one to two orders of magnitude
lower than that of persistent RNA viruses (e.g. hepatitis C virus
and human immunodeficiency virus) and persistent DNA viruses
(e.g. hepatitis B virus), which generally have pairwise nucleotide
diversity above 0.00532.
Neutralisation escape mutants have been isolated in 0.7% of
immunoprophylaxis-naïve RSV-infected subjects13, 5–9% of
RSV-breakthrough patients receiving palivizumab12,33 and 8% of
RSV-breakthrough cases receiving nirsevimab34. In our study,
isolates collected from 0.8% (2/264) of the immunoprophylaxis-
naïve participants were found to contain a nirsevimab resistance-
associated substitution at the consensus level. We also identified
an RSV-B minor variant with an amino acid change from serine
to proline at position 275 (S275P) of the F protein. Other amino
acid substitutions at this position have demonstrated resistance to
palivizumab (S275F/L)12. Whether the mutation S275P also alters
the neutralising activity of palivizumab requires further investi-
gation; however, all three mutations at this position replaced a
polar amino acid with a nonpolar one, which may result in sig-
nificant conformational or functional changes. It is important to
identify neutralisation escape mutants in immunoprophylaxis-
naïve children in the era before RSV monoclonal antibodies
become extensively used. It indicates the circulation of escape
mutants in the community even though they generally have a
selective disadvantage in the absence of monoclonal antibodies13.
Our findings that RSV-B had greater pairwise nucleotide
diversity and pairwise Manhattan distances than RSV-A both
indicate that, at least in our dataset, RSV-B had a more diverse
intrahost virus population than RSV-A. These results do not
correlate with the duration between symptom onset and sample
collection (Table 1), but are consistent with previous studies on
global RSV strains, which found that RSV-B has a higher
genome-wide evolutionary rate than RSV-A (7.47–7.76 × 10−4
substitutions/site/year vs. 5.68–6.47 × 10−4 substitutions/site/
year)35,36. This difference extends below the 3% threshold for
minority variant calling (Supplementary Fig. 6). On the basis of
these findings, we hypothesise that RSV-B is subject to greater
immune pressure (e.g. by innate immunity, neutralising
antibodies or T cell-mediated cytotoxicity) than RSV-A. This
hypothesis is in line with previous studies showing that intrahost
RSV diversity increased in response to an established immunity21
and that RSV-B has more amino acid alterations37, predicted O
glycosylation site changes37 and indel mutations36 in the G gene
than RSV-A, suggesting a stronger selective pressure acting on
RSV-B than on RSV-A.
RSV-B exhibited higher within-host diversity in older adults
than in infants in response to different immune pressures
between the two age groups. Of note, our dataset included only
eight adults, and this comparison was limited to seven adult
samples and 137 infant samples collected from those with RSV-B
infection. Further studies enrolling more adults would be of value
to delineate the difference in within-host diversity between dif-
ferent age groups. Furthermore, the temporal changes of pairwise
nucleotide diversity and minor variants were stochastic within
each infected individual, suggesting the driving force of evolu-
tionary dynamics in global RSV populations is more likely from
the selective pressure imposed at the population level than within
an individual host. Only samples that yielded sufficient RSV reads
were included in this study, so these temporal trends were con-
fined to samples collected over a short time frame (mostly within
5 days of symptom onset). Nonetheless, a study on seasonal
influenza virus also found limited evidence of positive selection at
the within-host evolutionary scale24.
The greater within-host virus diversity observed in RSV-B than
in RSV-A warrants separate testing and close monitoring of the
anti-RSV-B efficacy of vaccines and monoclonal antibodies that
are being developed. This is because the development of several
RSV vaccines in preclinical or clinical trials is based on the
nucleotide sequences or structure of RSV-A strains38–40. Some
studies have also shown that RSV-B had more fixed mutations in
the antigenic sites of the F protein at the consensus level41,
resulting in more variable in vitro and clinical susceptibility to
monoclonal antibodies than RSV-A. For example, in a phase 2b
trial of nirsevimab, the drug had reduced neutralising activity
against two RSV-B isolates collected from its recipients; one had a
mutation of N208S and the other had multiple mutations of I64T,
K68E, I206M and Q209R in the F protein34. A phase 3 trial of
another investigational RSV monoclonal antibody, suptavumab,
failed to meet its primary end point because all RSV-B strains
identified in the trial carried two amino acid changes in the F
protein (L172Q and S173L), conferring resistance to the drug8.
All RSV-B samples in our study also harboured these two amino
acid substitutions, except for one that encoded isoleucine instead
of leucine at position 173 (a nonpolar-to-nonpolar substitution).
We excluded genomic positions where consensus bases were
different from the calculation of Manhattan distance, to ensure
that between-host genetic distance would be driven by differences
in minor alleles rather than differences at the consensus level24.
We found that, outside the consensus-different positions, serial
samples from the same individual did not have a shorter pairwise
Manhattan distance than that of a randomly taken between-host
pair from the same country and season. This methodology change
makes our results robust to inter-host variation, in contrast to
previous studies on influenza virus and RSV, where distance
metrics were largely driven by consensus differences42,43.
Our findings suggest that RSV-B has a more diverse within-
host population than RSV-A, likely driven by selection pressure at
the host-population level. This difference between the two sub-
groups warrants close monitoring of vaccine efficacy and emer-
gence of neutralisation escape variants.
Methods
Sample collection. Nasopharyngeal swabs were collected from patients with
respiratory symptoms under 1 year old or over 60 years old, from London and
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Oxford, United Kingdom, Santiago de Compostela, Spain and Utrecht, the Neth-
erlands, during 2017–2020. These patients were enrolled in three clinical studies of
the REspiratory Syncytial virus Consortium in EUrope project (RESCEU, Clin-
icalTrials.gov identifiers: NCT0362757244, NCT0375676645 and NCT0362193046),
a European multicentre project investigating epidemiological, virological and
immunological characteristics of RSV infection. None of these participants had
received any RSV monoclonal antibody or investigational vaccine. RSV infection
was diagnosed using molecular point-of-care testing on the AlereTM i RSV plat-
form (Abbott, Illinois, US) in infant participants and on the GeneXpertⓇ influenza/
RSV system (Cepheid, California, US) in adult participants in a community setting,
and using antigen and/or PCR tests at a central laboratory in a hospital setting. A
nasopharyngeal swab was collected from each participant within 7 days of symp-
tom onset, and daily swabs were also collected from RSV-positive hospitalised
infant participants where possible until hospital discharge. After collection, swabs
were immersed in an M4RTⓇ transport medium, aliquoted, and frozen at −80 ∘C
until use.
The severity of an RSV infection was defined using the ReSVinet scale47 in
infants. This scale accounts for several clinical variables, including feeding
intolerance, medical intervention, respiratory difficulty, respiratory frequency,
apnoea, general condition and fever. The score ranges from 0 to 20; a score of 0–7
was defined as mild, a score of 8–13 as moderate and a score of 14–20 as severe. In
older adults, those who did not require any treatment or medical attendance were
defined as having mild disease, those requiring hospitalisation were defined as
having severe disease and the rest were defined as having a moderate RSV disease.
These clinical studies were conducted in accordance with the provisions of the
Declaration of Helsinki and were approved by the relevant ethics committees at
each site, including the University of Oxford, the Health Research Authority (IRAS
IDs: 224156 and 231136), the NHS National Research Ethics Service Oxfordshire
Committee A (reference number: 15/SC/0335), the South Central and Hampshire
A Research Ethics Committee (reference number: 17/SC/0522) and the London-
Central Research Ethics Committee (reference number: 17/LO/1210) in the UK;
Hospital Clínico Universitario de Santiago de Compostela, and Comité de Ética de
la Investigación de Santiago-Lugo (reference number: 2017/395) in Spain; the
Medical Ethical Committee, University Medical Center Utrecht (reference number:
17/563) and the Ethical Review Authority (reference number: NL60910.041.17) in
the Netherlands. All adult participants and the parents or guardians of all infant
participants provided written informed consent.
Nucleic acid isolation and whole-genome sequencing. All RSV-positive samples
were selected for whole-genome sequencing. Nucleic acid isolation, library con-
struction and sequencing were performed in four different batches. To minimise
the risk of RNA degradation, nucleic acid was extracted locally from primary
samples, and the extractions were scheduled as close as practical to the time of
sequencing.
Total nucleic acid extraction was carried out using the NucliSENSⓇ easyMAGⓇ
system (BioMérieux, Marcy-l’Étoile, France), following the manufacturer’s
instructions. Wherever possible, 500 μL of each sample was used to get 25 μL eluate
in the first and fourth batches, and 35 μL in the second and third batches.
Sequencing libraries were constructed using the methodology of targeted
metagenomics27, a modification of the veSEQ-HIV protocol48. A 12-μL aliquot of
each nucleic acid sample was first concentrated to 3 μL with RNAClean XP
magnetic beads (Beckman Coulter, California, United States). Dual-indexed
libraries for Illumina sequencing were then constructed using the SMARTer
Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian (Takara Bio USA,
California, United States), where first-strand reverse transcription was primed with
tagged random hexamers and double-stranded cDNA was synthesised with sets of
i5 and i7 index primers, as previously described elsewhere49. These gave unique
dual indexing (UDI) for the samples, thus minimising the risk of index
misassignment during sequencing. After 12 cycles of PCR amplification of the
cDNA, 10 μL of each library was pooled and purified using AMPure XP (Beckman
Coulter). A 750-ng aliquot was taken from the pool and captured using a
predesigned SureSelect RNA Target Enrichment multi-pathogen probe set
(Agilent, California, United States). This probe set (each 120 nucleotides long)
targeted more than 100 pathogenic bacteria and viruses, including both RSV-A and
RSV-B50. Sixteen cycles of PCR were performed for post-capture amplification, and
the final product was purified by AMPure XP.
Sequencing was performed on the Illumina MiSeq platform (Illumina,
California, US) with the MiSeq Reagent Kit v3 (600-cycle) for the first and third
batches, generating 265-bp and 300-bp paired-end reads, respectively. The second
and fourth batches were sequenced on the Illumina NovaSeq 6000 system with the
NovaSeq 6000 SP Reagent Kit v1.5 (300-cycle), generating 151-bp paired-
end reads.
Genome reconstruction. The first six bases of read 1 and the first three bases of
read 2 were clipped off to remove random hexamer primers and the SMARTer
adaptor sequences, respectively. An extra three bases at the 5′ end of MiSeq-
generated read 2 were also cut off as they had reduced quality. Trimmomatic
(v0.39)51 was then used to trimmed off adaptor sequences and low-quality bases
with a Phred score below 20 (option: Adaptors:2:10:7:1:true LEADING:20
TRAILING:20 SLIDINGWINDOW:4:20 MINLEN:50). De novo assembly of the
trimmed reads was carried out using both IVA (v1.0.8)52 and SPAdes (v3.14.1)53,
in each case selecting the contig sequences with a higher N50 for genome recon-
struction using shiver54. Internally, BLASTN (v2.7.1+)55 was used for read and
contig classification, MAFFT (v7.471)56 was used for sequence alignment and
Bowtie 2 (v2.4.1)57 was used for read alignment (option: --very-sensitive-local). A
minimum base quality of 35 and mapping quality of 30 were required for a base or
an alignment to be counted as mapped. Mapped RSV reads were deduplicated with
Picard MarkDuplicates (v2.18.14, https://broadinstitute.github.io/picard/). Pre-
deduplicated per-position mapped read counts, generated by shiver, were used for
downstream within-host virus diversity analysis.
Within-host virus diversity analysis. Only samples generating more than 10,000
unique (i.e. deduplicated) RSV reads and containing a single subgroup of RSV were
included in within-host virus genetic diversity analysis. We have previously shown
that RSV viral load highly correlates with the number of unique RSV reads gen-
erated by this sequencing method27, consistent with high-quality RNA being
recovered in a quantitative way. Ten thousand unique RSV reads correspond to a
viral load of ~2.4 × 106 copies/mL. Allele frequencies were calculated at each
genomic position, excluding those supported by fewer than 200 reads. The choice
of this cut-off was based on a predefined criterion that 90% of the included samples
had at least 80% of the genome fulfilling this cut-off (Supplementary Fig. 7).
Cumulative MAF was defined as 1 minus major allele frequency, and polymorphic
sites were those with a cumulative MAF of ≥3%. Mean cumulative MAF per sample
was calculated as the sum of cumulative MAF at each genomic position divided by
the total number of positions. Minor variants, or intrahost single nucleotide var-
iants, were defined as variants with an allele frequency of ≥3% and <50%.
Intrahost virus diversity was estimated as pairwise nucleotide diversity (π)58.
The proportion of pairwise nucleotide differences (D) at each genomic position was
calculated as
Di ¼
Ai ´Ci þ Ai ´Gi þ Ai ´Ti þ Ci ´Gi þ Ci ´Ti þ Gi ´Ti
ðN2i  NiÞ=2
ð1Þ
where Ai, Ci, Gi and Ti represent the copy number of allele A, C, G and T,
respectively, and Ni is the total count of the four alleles (i.e. depth of coverage) at a
given locus i, so Ni= Ai+ Ci+Gi+ Ti. Loci with a total count of less than 200








where L is the number of genomic positions with a read depth of at least 200×.
Manhattan (L1-norm) distance was used to compare within-host diversity levels
between samples, calculated as















where di is the distance between two samples at a given locus i with vectors p and q
containing relative frequencies of four possible alleles (i.e. A, C, G and T), M is the
Manhattan distance between the coding sequences of two samples, N is the number
of coding sequence positions where both samples have the same consensus base
and a read depth of at least 200× and S is the total length of the coding sequence.
To remove potential background noise in Manhattan distance calculations, allele
frequencies of <3% were changed to 0, and those of >97% were changed to 100%.
Nucleotide positions were numbered from the first base of the coding sequence
of each gene according to the NCBI reference sequences with the accession
numbers of NC_038235 and NC_001781 for RSV-A and RSV-B, respectively.
Amino acid positions were numbered from the first methionine of each protein
according to the same NCBI reference sequences.
Phylogeny reconstruction. Maximum likelihood phylogenies of consensus coding
sequences, supported by at least two unique (deduplicated) RSV reads, were esti-
mated using RAxML (v8.2.12)59 with the general time-reversible nucleotide sub-
stitution model and gamma-distributed rate heterogeneity. Bootstrapping with
1000 replicates was used to assess the robustness of tree topologies. Pairwise
patristic distances were calculated from the maximum-likelihood trees using the
cophenetic function of the R package ape (v5.4-1)60. Phylogenetic trees were
visualised using the R package ggtree (v2.2.4)61.
Statistical analysis. Continuous variables were summarised using mean, median,
maximum and minimum. All comparisons of continuous variables between groups
were conducted by two-tailed Mann–Whitney U-tests (two groups) or
Kruskal–Wallis tests (three groups). Post hoc application of the
Benjamini–Hochberg procedure was used to control false discovery rates for
multiple testing. Chi-square tests with Yates’ continuity correction were used for
contingency analysis; Fisher’s exact tests were performed when the expected value
of a cell was less than 5. Logistic regression was employed to model a binary
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dependent variable while adjusting for a covariate. Two-tailed Pearson correlation
analysis was used to evaluate the relationship between two variables. Temporal
changes of a variable were determined by ordinary least-squares linear regression.
Two approaches were applied to account for batch effects on the comparisons of
diversity metrics: (i) including batch as a regression covariate (e.g. regression of
pairwise nucleotide diversity on sampling country, sampling season, RSV sub-
group, RSV read count, participant age group, disease severity and ‘batch’ as in
Supplementary Table 2); and (ii) standardising the values within each batch to z-
scores, that is, to a mean of zero and a standard deviation of 1 (e.g. Mann–Whitney
U-test on z-score standardised pairwise nucleotide diversity as in Fig. 2). Missing
data were imputed using the aregImpute function, implemented in the R package
Hmisc (v4.5-0)62. All statistical analyses were performed using R (v4.0.2)63. P
values or adjusted P values of less than 0.05 were considered to indicate statistical
significance.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The sequencing read data generated in this study have been deposited in the European
Nucleotide Archive under study accession PRJEB34042. The RSV genomic sequences
generated in this study have been deposited in GenBank under accession numbers LR699315
LR699726, LR699734, LR699736-LR699744 and MZ515551-MZ516143. The RSV reference
sequences used in this study are available in GenBank under accession numbers NC_038235
and NC_001781. The associated sample and de-identified clinical information used in this
study is provided in Supplementary Data 1.
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